Skip to the page

Data / Form D filings / Xact Bio, Inc.

Xact Bio, Inc.: Form D filing

Xact Bio, Inc., a biotechnology company in Boston, MA, filed a Form D with the SEC in 2026. The latest, on September 28, 2026, reports $10 million sold of a $18 million offering to 3 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
501 BOYLSTON STREET, 9TH FLOOR, Boston, MA, 02116
Phone
(000) 000-0000
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2024
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2157427

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Sep 28, 2026New notice$17,999,997$9,999,999$7,999,9983Sep 11, 2026sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Eric GreenExecutive Officer, Director
Uciane ScarlettExecutive Officer, Director
Chengjung LaiDirector
Jian ShaoDirector

Other biotechnology companies in Massachusetts that filed recently

Every Form D from the week of Sep 28, 2026 · All recent filings in Massachusetts · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Xact Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.